Lyell Immunopharma (LYEL) investor relations material

Company overview and business model

• Late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer patients, targeting both hematologic malignancies and solid tumors.

• Focuses on engineering patients' immune cells with proprietary enhancements to improve cancer cell killing and durability of response.

• Incorporated in June 2018 in Delaware, headquartered in South San Francisco, CA.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of shares by the selling stockholder; all shares sold are for the account of ICT Holdings.

• Registration expenses are split 50/50 between the company and ICT Holdings; ICT Holdings bears all underwriting discounts, commissions, and transfer taxes.

Risk factors and disclosures

• Investment involves a high degree of risk, with risks detailed in the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, incorporated by reference.

• Forward-looking statements are subject to significant uncertainties and actual results may differ materially.